Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
April 8, 2019
aTyr Pharma to Present Poster at the American Thoracic Society 2019 International Conference
SAN DIEGO, April 08, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based ...
April 8, 2019
Zogenix Receives Refusal to File Letter from U.S. Food and Drug Administration for FINTEPLA® New Drug Application
EMERYVILLE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it received a ...
April 8, 2019
Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
AUSTIN, Texas, April 07, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for ...
April 8, 2019
Genkyotex to Present Updated Interim Results From Phase 2 Trial of GKT831 in Primary Biliary Cholongitis at 2019 EASL International Liver Congress (ILC)
ARCHAMPS, France, April 08, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0011790542 - GKTX), a biopharmaceutical company and the leader in NOX therapies, ...
April 8, 2019
CytoSorbents to Present at the H.C. Wainwright Global Life Sciences Conference 2019 London
MONMOUTH JUNCTION, N.J., April 8, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation ...
April 8, 2019
Oncolytics Biotech(R) Announces First Patient Treated in Company's AWARE-1 Window of Opportunity Study of Pelareorep in Breast Cancer
CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 8, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic ...
April 8, 2019
Inspire Medical Systems, Inc. Announces Three New Positive Coverage Policies Issued by Blue Cross Blue Shield Plans
MINNEAPOLIS, April 08, 2019 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative ...
April 8, 2019
Check-Cap Initiates U.S. Pilot Study of C-Scan® for Colorectal Cancer Screening
ISFIYA, Israel, April 8, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (NASDAQ:CHEKZ), a clinical-stage medical diagnostics company advancing the development of ...
April 8, 2019
TYME’s SM-88 First Human Study in Patients with Metastatic Cancer Published in the Journal, Investigational New Drugs
NEW YORK, April 08, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that the results ...
April 8, 2019
Actinium's Leading Clinical, Preclinical, Production and IP Efforts Related to Actinium-225 Highlighted at Preeminent Targeted Alpha Therapy International Symposium
NEW YORK, April 8, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) today highlighted its broad presence at the 11th Targeted-Alpha-Therapy International Symposium (TAT) ...
April 8, 2019
Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT003, Nasal Nalmefene, for Treatment of Synthetic Opioid Overdose
SANTA MONICA, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today ...
April 8, 2019
Bellerophon Announces Agreement with FDA on Regulatory Approval Pathway for INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
WARREN, N.J., April 08, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it has reached ...
April 3, 2019
Inventiva to Participate at the H.C. Wainwright Global Life Sciences Conference
Daix (France), April 3, 2019 – Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas ...
April 3, 2019
Aileron Therapeutics Completes $26M Private Placement
WATERTOWN, Mass., April 03, 2019 (GLOBE NEWSWIRE) --  Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and ...
April 3, 2019
Genocea to Present at 18th Annual Needham Healthcare Conference
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark, president ...
April 3, 2019
InspireMD, Inc. Announces Proposed Public Offering of Common Stock
TEL AVIV, Israel, April 03, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke ...
April 3, 2019
OSE Immunotherapeutics Presents New Clinical and Preclinical Data on its Immuno-Oncology Portfolio at AACR 2019
NANTES, France, April 02, 2019 (GLOBE NEWSWIRE) -- OSEImmunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), today announced that new clinical and preclinical data on its products in ...
April 3, 2019
Genocea Presents Data at AACR 2019 Supporting Utility of ATLAS™ Platform in Predicting Melanoma Patient Response to Immune Checkpoint Inhibitors
CAMBRIDGE, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing neoantigen cancer immunotherapies, today announced the presentation of data ...
April 3, 2019
Vermillion Exhibits OVA1 Ethnic Disparity Performance Poster at the American Association for Cancer Research (AACR) Annual Meeting
AUSTIN, Texas, April 02, 2019 (GLOBE NEWSWIRE) -- Vermillion, Inc. (VRML), a bioanalytical-based women’s health company focused on gynecologic disease, is being represented at the ...
April 3, 2019
ADMA Receives Department of Health and Human Services U.S. License
RAMSEY, N.J. and BOCA RATON, Fla., April 02, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical ...
Page 21 of 158